Nouveau Marché gets first IPO in three years

Immuno-Designed Molecules, the cancer treatment specialist, plans to test the Nouveau Marché in the first significant flotation for three years. UBS is leading the deal.

The float comes amid a difficult market for initial public offerings and weak support for the biotechnology sector.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump